BPS found to be a safe and effective option
BPS found to be a safe and effective option
Study targets therapeutic GI endoscopies
Researchers report that, compared with conventional sedation, balanced propofol sedation (BPS) using propofol with midazolam and meperidine provided higher provider satisfaction, better patient cooperation, and similar adverse event profiles in patients undergoing therapeutic endoscopic procedures.
This is the first prospective study of BPS in direct comparison with conventional sedation. The researchers say that this study provides further evidence to support the adoption of endoscopist-directed BPS for therapeutic endoscopy. The study appears in the February issue of GIE: Gastrointestinal Endoscopy, the monthly journal of the American Society for Gastrointestinal Endoscopy.
Balanced propofol sedation (BPS) combines small incremental doses of propofol with single induction doses of benzodiazepines and opioids under the direction of a physician that is not an anesthesiologist. Because BPS usually targets moderate sedation, adequate amnesia and analgesia can be achieved with concomitant administration of benzodiazepines and opioids.
Study lead author Chang Kyun Lee, MD, PhD, Kyung Hee University School of Medicine, Kyung Hee University Hospital, Seoul, Korea, said, "The present study was conducted to compare the safety and efficacy of BPS, propofol in combination with midazolam and meperidine, with conventional sedation, midazolam and meperidine, in patients undergoing therapeutic GI endoscopic procedures. We found that BPS provided higher health care provider satisfaction, better patient cooperation, and it had similar adverse event profiles to conventional sedation."
Researchers report that, compared with conventional sedation, balanced propofol sedation (BPS) using propofol with midazolam and meperidine provided higher provider satisfaction, better patient cooperation, and similar adverse event profiles in patients undergoing therapeutic endoscopic procedures.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.